Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma

•This was a retrospective analysis of 231 patients with a high-risk chromosomal abnormality (HRMM) receiving lenalidomide (Len)-based post-transplantation maintenance.•Maintenance with Len-based combinations did not improve outcomes in the entire cohort.•In patients with HRMM other than 1q+, there was a trend toward improved PFS with Len-based combinations for maintenance.